BRISBANE, Calif., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the ...
BRISBANE, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of ...
FDA has determined that NRx’s Abbreviated New Drug Application (ANDA) is “substantially complete” and received for review.
WILMINGTON, Del., June 5, 2025 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), a clinical-stage biopharmaceutical company, today announced the transmission of its Abbreviated New Drug ...
TipRanks on MSN
NRx Pharmaceuticals (NASDAQ: NRXP) Announces FDA Receipt of ANDA for KETAFREE With July 2026 Review Goal Date
Austin, Texas, United States, December 2nd, 2025, FinanceWire NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage ...
DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on ...
Civica Rx is asking fellow generic drugmakers to aid it in combating drug shortages. Those drugmakers considering retiring or withdrawing their abbreviated new drug applications, or ANDAs, are being ...
FDA has determined that NRx's Abbreviated New Drug Application (ANDA) is "substantially complete" and received for review. Assigned GDUFA goal date is July 29, 2026.NRx has applied to FDA for use of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback